Background: There is biologic plausibility as to why infection with Helicobacter pylori, the leading cause of gastric cancer, may also increase the risk of colorectal cancer, but the epidemiologic findings have been inconsistent. We assessed the association of H. pylori protein-specific infection and colorectal cancer risk in the prospective cohort, the Southern Community Cohort Study.
Introduction
Infection with Helicobacter pylori, which induces chronic inflammation in the gastric mucosa, is the strongest known risk factor for gastric cancer. Recent studies suggest that H. pylori infection may also increase the risk of colorectal cancer, and although these findings have been inconsistent, two recent meta-analyses found significant 40% to 50% increased odds for colorectal cancer among individuals with evidence of a current or past H. pylori infection (1, 2) . A primary mechanism by which H. pylori infection might increase the risk of colorectal cancer is via an increase in the release of gastrin (3), a peptide hormone whose main role is to stimulate gastric acid secretion, but which also functions as a mitogen (4) . Chronic gastritis that results from persistent H. pylori infection is associated with hypergastrinemia, as H. pylori infection-related gastritis reduces acid secretion, which in a negative feedback loop induces the production of high-gastrin levels (3) . H. pylori infection could also increase risk of colorectal cancer through mechanisms related to those secondary to chronic infection and/or alteration of the bacterial flora that comprise the gastrointestinal microenvironment (4) (5) (6) . Other evidence that colorectal and gastric cancers may share some aspects of a common etiology include the facts that colorectal cancer has consistently been found to be the most common synchronous cancer among patients with gastric cancer (7, 8) ; second primary gastric cancers are increased following colorectal cancer diagnosis (9) ; and, correspondingly, second primary colorectal cancers are increased following gastric cancer diagnosis (10) .
The majority of the previously published studies examining the association between H. pylori and colorectal cancer risk did not take into account H. pylori strain type. Because more than 50% population of the world is infected with the bacteria and only a small percentage of those individuals develop cancer, it is important that both host and bacterial factors are considered when assessing associations with disease. Furthermore, H. pylori has colonized the stomach of humans for more than 50,000 years and has evolved over time to become highly genetically diverse (11) . Although the authors of the most recent study of the association of H. pylori and colorectal cancer risk did stratify by presence of the H. pylori protein and known gastric cancer virulence factor cytotoxin-associated antigen (CagA), the association found with CagA-positive strains was not substantially stronger than that with H. pylori seroprevalence alone (significant ORs of 1.20 and 1.18, respectively; ref. 12 ). In addition, this case-control study collected blood samples at hospitalization for cancer treatment and, thus, the measurement of H. pylori status among cases may have been hindered by presence of the tumor and/or the initiation of cancer treatment. Finally, as the authors discuss themselves, they did not inspect the association of other H. pylori virulence factors, such as VacA, HcpC, and GroEL, with colorectal cancer risk. Only two other studies to our knowledge have investigated CagA status and colorectal cancer risk; in the Alpha-Tocopherol, Beta-Carotene Study cohort of Finnish male smokers, no association was found with H. pylori seropositivity, and there was only a suggestion of an increase in risk for colorectal cancer among persons seropositive to CagA [OR, 1.17; 95% confidence interval (CI), 0.74-1.84; ref. 13 ], whereas in a small hospital-based case-control study in Israel composed of 67 cases of colorectal adenocarcinoma and 45 individuals hospitalized for transesophageal echocardiography as controls, CagA seropositivity was linked to a more than 10-fold increase in risk for colorectal cancer (OR, 10.6; 95% CI, 2.7-41.3; ref. 14) .
In addition, none of the published studies of H. pylori and colorectal cancer risk have included a substantial number of African Americans, the racial/ethnic group with the highest incidence of and mortality from colorectal cancer in the United States (15) . We recently found an exceptionally high prevalence of H. pylori infection among African American participants in the Southern Community Cohort Study (SCCS), composed of individuals recruited from community health centers (CHC) in the southeastern United States that serve primarily lowincome and uninsured persons (16) . In fact, both African Americans and Whites in the SCCS have seroprevalences that rival developing countries (89% and 69%, respectively) and African Americans are significantly more likely than Whites to be infected with 8 different H. pylori proteins suspected to be gastric cancer-associated virulence constituents, including CagA (OR, 6.4; 95% CI, 4.5-9.1) and VacA (OR, 2.3; 95% CI, 1.5-3.5; ref. 16 ).
The present study sought to assess the association of H. pylori and colorectal cancer risk by including H. pylori protein-specific analyses of the bacteria in a prospective, nested case-control design among an understudied population with a high prevalence of H. pylori, the SCCS.
Materials and Methods

Study population
As previously described in detail (17) , the SCCS is a prospective cohort study that enrolled approximately 86,000 men and women from 12 southeastern states from 2002 to 2009. Participants, ages 40 to 79, were primarily (86%) recruited from CHCs, institutions offering basic health and preventative services mainly to the medically uninsured and underinsured as well as by mail (14%). Individuals recruited from CHCs participated in in-person, comprehensive computer-assisted interviews that obtained information on demographic and lifestyle factors as well as regular diet, personal and family medical history, and health services use. The SCCS was reviewed and approved by Institutional Review Boards at Vanderbilt University and Meharry Medical College (Nashville, TN). Written informed consent was obtained from all study participants. The individuals recruited by mail completed an article version of the same baseline questionnaire. Individuals recruited at the CHCs were also asked to donate venous blood samples (20 mL), which were then immediately refrigerated. The samples were then shipped overnight to Vanderbilt University to be centrifuged the next day, and then stored at À80
C. For the assay of H. pylori protein antibodies as examined in the present project, a serum sample for each study subject was aliquoted into 50 mL portions.
Case identification
Incident colorectal cancer cases (International Classification of Diseases-Oncology, ICD-O-3; codes C180-189, C199, and C209) diagnosed after entry into the SCCS were identified through linkage with state cancer registries from the 12-state study area and/or from National Death Index mortality records. A total of 188 colorectal cancer cases were identified as occurring after biospecimen collection and before the end of 2011, among those SCCS participants recruited at CHCs who donated a blood sample.
Control selection
For each case, 2 controls were chosen, matched on age (AE2 years), race (African American, White, or other), sex, menopausal status (for women), CHC site, date of sample collection (AE6 months), and availability of serum. Matching with these criteria to identify 2 controls was successful for 87% of cases. For 10% of cases, the requirement for the control being recruited from the same CHC as the case was relaxed to a CHC in the same state and for the remaining 3% of cases, the requirement for matching on CHC location was dropped altogether. Of 376 controls chosen in this manner, 3 were excluded because of missing baseline data, 1 was missing serum, 1 was a duplicate, and 1 was not matched, resulting in 370 controls and 188 cases for the present study.
H. pylori multiplex serology
Because previously described, H. pylori multiplex serology uses a glutathione S-transferase capture immunosorbent assay combined with fluorescent bead technology (Luminex) to detect antibody levels to a constellation of IgA, IgM, and IgG values to 15 H. pylori proteins (UreA, Catalase, GroEL, NapA, CagA, CAgM, Cagd, HP0231, VacA, HpaA, Cad, HyuA, Omp, HcpC, and HP0305; refs. 18, 19) . These proteins were chosen for the assay based on known surface exposure and immunogenicity in two-dimensional immunoblot analyses (UreA, Catalase, NapA, CagA, HP231, VacA, and HpaA), serologic association with gastric cancer (GroEl, Cad, HyuA, Omp, and HcpC) and/or gastric ulcer (HP305 and CagM), and specific recognition in H. pylori-positive sera (Cagd and CagM). All sera are analyzed once within a single assay day. Antigen-specific cutoff points were calculated [mean median reporter fluorescence intensity (MFI) plus three times SD, excluding positive outliers] in 17 H. pylorinegative sera previously classified for H. pylori status run within the same experiment. Defining H. pylori seropositivity as reactivity with at least 4 proteins has shown good agreement (k ¼ 0.70) with commercial serologic assay, resulting in 89% sensitivity and 82% specificity (18) . For quality control, 18 samples from one-pooled sample were included in the assay. The determination of seropositivity for all of the H. pylori proteins was strongly consistent and the interassay coefficient of variation (CV) ranged from 10% to 21% (notably, the CagA, CV was 13% and the VacA, CV was 15%).
Statistical analysis
To assess the individual associations of seropositivity to each of the 15 H. pylori proteins with colorectal cancer risk, conditional logistic regression was used in separate models for each protein to determine ORs and 95% CIs. To determine the possibility of confounding by baseline characteristics, Pearson c 2 test was used to assess differences between cases and controls, between individuals seropositive and seronegative for H. pylori, and between individuals seropositive and seronegative for VacA. No baseline characteristic was found to be associated with both colorectal cancer risk and H. pylori or VacA status. Smoking status was the only baseline factor associated with colorectal cancer risk, but it was not associated with H. pylori or VacA status. Potential confounders associated with H. pylori or VacA status, including education, income, regular use of aspirin, vitamin supplement use, and colorectal cancer screening history, were not associated with colorectal cancer risk in this population, and like smoking status, inclusion of these variables in the model did not alter the main effects by 10% or more. Race was strongly associated with H. pylori status, but this demographic characteristic could not confound the association as controls were matched to cases by race, and conditional logistic regression ensured that the association between H. pylori and colorectal cancer compared risk among raceconcordant sets.
To examine a potential dose-response relationship between the level of antibodies and colorectal cancer risk, we created quartiles of antibody levels (MFI) for each of the 15 H. pylori proteins assessed on the basis of the distribution among control subjects. Conditional logistic regression was used again to determine the association of increasing quartile of H. pylori protein-specific antibody level and colorectal cancer risk with indicator variables representing antibody levels, using the lowest quartile as the reference category. To test for a linear trend across antibody quartiles of each protein, a continuous variable was created with the values of 0, 1, 2, and 3 for the 4 quartiles. The Bonferroni correction for multiple testing was considered but rejected as the 15 H. pylori proteins assessed are significantly correlated with one another.
To further explore the relationship between H. pylori status and risk of colorectal cancer, we assessed the association in separate models for colon cancer (C180-189) and rectal cancer (C199 and C209), for cancer of the right/ascending colon (C180-184) and cancer of the left/ descending colon (C185-187), for cancers diagnosed at local, regional, and distant stages, individually, and for cancers by age at diagnosis (separately, in tertiles and dichotomously comparing <60-to 60þ-year-olds). For these models, we again conducted conditional logistic regression, and for analyses by stage adjusted for a marker of socioeconomic status (high school graduate, yes vs. no) and for a history of colorectal cancer screening (ever vs. never). We examined effect modification of the association of H. pylori status and colon cancer risk through models stratified by race and sex, and assessment of an interaction term using the likelihood ratio test.
Results
Baseline characteristics of colorectal cancer cases and controls were similar in most respects, including markers of socioeconomic status and body mass index (Table 1) . Although the great majority of individuals in this population (87.1%) were seropositive for H. pylori (i.e., were positive to at least 4 of the proteins), individuals seronegative for H. pylori were significantly more likely to be White (rather than African American), have obtained a high school or greater education, have a household annual income above $15,000, be a regular aspirin user, and use vitamin supplements. The same proportion of colorectal cancer cases and controls (87%) was seropositive to H. pylori overall, leading to no difference in risk (OR, 1.03; 95% CI, 0.59-1.77).
Seropositivity to 5 of the 15 H. pylori proteins investigated-VacA, HP231, HP305, NapA, and HcpC-was associated with a statistically significant 60% to 80% increase in odds of colorectal cancer risk ( Table 2 ). The association of seropositivity to 9 of the other 10 H. pylori proteins was also in the direction of increased risk, the one exception being CagA (OR, 0.99; 95% CI, 0.64-1.53). When examining the associations with colon cancer alone, the association of these 5 proteins became even stronger, resulting most significantly in a more than 2-fold increase in risk for individuals seropositive to VacA (OR, 2.24; 95% CI, 1.22-4.11). The association between CagA seropositivity and colon cancer moved in the positive direction, although it did not reach statistical significance (OR, 1.26; 95% CI, 0.74-2.16). Overall H. pylori seropositivity was A significant positive dose-response association by quartile of antibodies for risk of colorectal cancer was found for 7 of 15 H. pylori proteins assessed (VacA, HP231, HP305, NapA, HcpC, Cad, and GroEL; Table 3 ). When examining these trends with colon cancer only, the doseresponse trends for each of these 7 H. pylori proteins were strengthened (although statistical significance was lessened, because of smaller numbers), statistical significance in trend was reached for an additional protein (UreA), and a suggestion of a dose-response association was found for CagA (P for trend ¼ 0.06). No dose-response associations between antibodies to H. pylori proteins and risk of rectal cancer were found.
Discussion
In this prospective study of a predominantly lowincome population with a high prevalence of H. pylori infection, seropositivity to 5 H. pylori-specific proteins, most notably VacA, was associated with a 60% to 80% VacA is a multifunctional toxin that targets the mitochondria through the formation of pores in the epithelial cell membrane, entering host cells through vacuoles in the cytoplasm, where it induces apoptosis as well as blocks T-cell proliferation and induces cell-cycle arrest (20) . In vivo experiments have found that expression of VacA plays an important role in the colonization of the host (21). Although most strains of H. pylori possess the VacA gene and express the associated protein, less than half produce the most active form (22) . The association of increased levels of antibodies to VacA with colorectal cancer risk may be related to gastrin, a peptide hormone that induces gastric acid secretion and stimulates protein expression of COX-2 (23) . Laboratory studies have found that administration of VacA-positive strains of H. pylori (as well as CagA-positive H. pylori strains) induces an inflammatory response and increases gastrinemia (24) (25) (26) , and that after H. pylori eradication, serum gastrin levels decrease significantly (27) . An association between highgastrin levels and colorectal cancer risk has been suggested in several studies of human populations (28) (29) (30) , although the association only reached significance in one study (30) . In the most recent study of the gastrin-colorectal cancer association, mean levels of gastrin did not differ between cases and controls, although significantly higher levels were seen among patients with lymph node metastasis compared with patients without (P ¼ 0.03; ref. 29) .
With the exception of the present study, no other studies to our knowledge have examined colorectal cancer risk with H. pylori subtypes other than CagA-positive strains. About gastric cancer, serum antibodies to both CagA and VacA have been found to be associated with increased risk of disease as well as a stronger inflammatory response (31) . Some studies have even found stronger associations for gastrointestinal disease among individuals with VacA antibodies than those with CagA antibodies (32) (33) (34) . However, overall, the findings for the association of VacA antibodies and gastrointestinal pathology are inconsistent, with studies that find positive associations with disease (32, 34, 35) and those that find null associations (31, 36) .
Although in the current study, we found a null association of CagA with colorectal cancer risk, the association of colon cancer risk with CagA-positive strains (OR, 1.26; 95% CI, 0.74-2.16) is similar to what has been seen in other studies, although it did not reach significance in our analysis. It is possible that differences in risk associated with CagA-positive H. pylori might emerge if one could differentiate CagA isoforms [i.e., phylogeographic origin of the strain and/or Glu-Pro-Ile-Tyr-Ala (EPIYA) motifs], as has been done in studies of gastric cancer (37) (38) (39) , although this requires the use of gastric specimens, rather than blood samples that are collected in most prospective studies. In addition, the present study found no evidence of an interaction by VacA and CagA strain (data not shown), whereby a VacA-CagA interaction has been suggested in gastric cancer etiology (40) .
In the present study, the strongest associations with increased level of VacA antibodies were found for colon cancer and specifically cancer of the right colon as well as for colon cancer diagnosed at earlier ages and presenting at later stage. These results conflict with a case-control study of overall and CagA-positive H. pylori and colorectal cancer risk in Germany that included 1,712 cases and 1,669 controls and found stronger associations with cancer of the left colon and rectum and with early-stage tumors (12) . However, VacA status was not assessed and the cases were recruited during their hospital stay or even after surgery, which could affect the measurement of H. pylori antibodies.
Our findings of significant, strong dose-response associations of VacA antibodies with cancer of the right colon and cancers diagnosed at late stage and early onset provoke further questions. Because our findings are new and the interactions observed not specified a priori, and because our sample is of only moderate size, the results need replication in additional prospective studies before causal inferences could be considered. Also, as seropositivity to the 5 H. pylori proteins associated with colorectal cancer risk was highly correlated, we did not have the power to investigate the independent effects of each, although the results suggested that the findings seem to be primarily due to the association of VacA. There are mechanistic pathways, including gastrin production, gastric atrophy, and the expression of COX-2, that might explain causality, but the presence of high levels of VacA antibodies could also be an indicator of a different underlying factor that we have not measured, such as baseline inflammatory state of the host. However, because of the high prevalence of H. pylori in the population we studied, and even in the general U.S. population for whom it is estimated that 53% of African Americans and 22% of Whites are infected with H. pylori (41), the potential for a causal relationship needs to be explored in depth, as should it exist, opportunity for targeted cost-effective cancer prevention through H. pylori eradication therapy in high-risk populations could be explored.
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